Novo Nordisk has announced that its highly anticipated weight-loss drug, CagriSema, did not achieve its primary goal in a head-to-head trial against Eli Lilly's tirzepatide.
At the heart of this news is a clinical trial concept called non-inferiority. Essentially, Novo Nordisk needed to show that CagriSema was not meaningfully worse than tirzepatide. However, the results showed a weight loss of about 23% for CagriSema, compared to 25.5% for tirzepatide. This 2.5 percentage-point gap was significant enough to miss the non-inferiority target, cementing tirzepatide's reputation as the more potent option.
This outcome, while disappointing for Novo, was not entirely a surprise. First, previous large-scale studies on CagriSema, known as REDEFINE-1 and REDEFINE-2, had already shown weight loss percentages in the range of 15% to 23%. This was impressive, but it consistently fell short of the “over 25%” benchmark that investors and doctors were hoping to see, a level tirzepatide had already reached.
Second, the competitive bar was set incredibly high. In a prior head-to-head trial called SURMOUNT-5, Lilly's tirzepatide had already demonstrated clear superiority over Novo's current blockbuster, semaglutide (the active ingredient in Wegovy and Ozempic). This meant any new drug from Novo, including CagriSema, had to outperform not just its predecessor but also a competitor that had already won a direct comparison.
Finally, the broader context amplified the impact of this clinical result. Recently, the FDA decided not to add suicide risk warnings to this class of drugs (GLP-1s), shifting the competitive focus from safety to pure efficacy. With safety concerns eased, doctors and insurance companies are more likely to prefer the drug that delivers the most weight loss. This, combined with Lilly's multi-billion dollar investments to expand its manufacturing capacity, gives it a powerful advantage in the market.
In conclusion, this trial result is more than just a single data point. It solidifies a broader narrative of Lilly's leadership in the obesity market, backed by superior efficacy, a strong pipeline, and the capacity to meet soaring demand. For Novo Nordisk, the pressure now shifts to its next-generation drug, amycretin, to close the gap in the years to come.
- Glossary
- Non-inferiority trial: A clinical study designed to show that a new treatment is not unacceptably worse than an existing, standard treatment.
- GLP-1 (Glucagon-like peptide-1) receptor agonists: A class of drugs that mimic a gut hormone to help control blood sugar, slow digestion, and reduce appetite. They are used for both diabetes and weight management.
- Head-to-head trial: A study that directly compares two or more treatments against each other, rather than against a placebo.